Literature DB >> 10776695

Beta-thalassaemia intermedia in Lebanon.

M Qatanani1, A Taher, S Koussa, R Naaman, C Fisher, M Rugless, J Old, L Zahed.   

Abstract

Approximately one third of thalassaemia patients on record in Lebanon have thalassaemia intermedia. We have analysed three factors in a panel of 73 patients with this less severe form of the disease in our population: mild beta-globin gene mutations, deletions in the alpha-globin gene and the presence of a polymorphism for the enzyme Xmn I in the Ggamma-promoter region. The results show that the most important contributing factor is the beta-genotype: 68% of patients have a mild beta+ mutation (IVSI-6, cd29, -88 or -87), while 26% of patients are positive for the Xmn I polymorphism associated with increased production of HbF, which showed strong linkage to particular mutations (IVSII-1, cd8 and cd30). However, the genotype phenotype correlation is difficult, because many patients were initially misdiagnosed as thalassaemia major and were started early on regular blood transfusions, which was stopped later on. This illustrates well the importance of an early accurate diagnosis of thalassaemia intermedia for appropriate clinical management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10776695     DOI: 10.1034/j.1600-0609.2000.90087.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  Molecular characterization of β-thalassemia intermedia: a report from Iran.

Authors:  Aida Arab; Morteza Karimipoor; Ali Rajabi; Mohammad Hamid; Sedeigheh Arjmandi; Sirous Zeinali
Journal:  Mol Biol Rep       Date:  2010-12-01       Impact factor: 2.316

2.  Laboratory diagnosis for thalassemia intermedia: Are we there yet?

Authors:  Saqib Ansari; Nabil Rashid; Anny Hanifa; Saima Siddiqui; Bushra Kaleem; Arshi Naz; Kousar Perveen; Zeeshan Hussain; Iqra Ansari; Qammar Jabbar; Tahir Khan; Muhammad Nadeem; Tahir Shamsi
Journal:  J Clin Lab Anal       Date:  2018-09-17       Impact factor: 2.352

3.  Role of XmnIgG Polymorphism in Hydroxyurea Treatment and Fetal Hemoglobin Level at Isfahanian Intermediate β-Thalassemia Patients.

Authors:  Majid Motovali-Bashi; Tayyebeh Ghasemi
Journal:  Iran Biomed J       Date:  2015-05-30

4.  β -thalassemia intermedia in Northern Iraq: a single center experience.

Authors:  Nasir A S Al-Allawi; Sana D Jalal; Ameen M Mohammad; Sharaza Q Omer; Raji S D Markous
Journal:  Biomed Res Int       Date:  2014-02-27       Impact factor: 3.411

5.  Xmn1-158 γGVariant in B-Thalassemia Intermediate Patients in South-East of Iran.

Authors:  Ebrahim Miri-Moghaddam; Sara Bahrami; Majid Naderi; Ali Bazi; Morteza Karimipoor
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-04-01

6.  Genotype-phenotype association analysis identifies the role of α globin genes in modulating disease severity of β thalassaemia intermedia in Sri Lanka.

Authors:  Shiromi Perera; Angela Allen; Ishari Silva; Menaka Hapugoda; M Nirmali Wickramarathne; Indira Wijesiriwardena; Stephen Allen; David Rees; Dimitar G Efremov; Christopher A Fisher; David J Weatherall; Anuja Premawardhena
Journal:  Sci Rep       Date:  2019-07-12       Impact factor: 4.379

7.  Molecular Characterization and Disease-Related Morbidities of β-Thalassemia Patients from the Northeastern Part of Iraq.

Authors:  Shaema Amin; Sana Jalal; Kosar Ali; Luqman Rasool; Tara Osman; Omed Ali; Abdalhamid M-Saeed
Journal:  Int J Gen Med       Date:  2020-12-09

8.  Report of a rare co-incidence of congenital factor V deficiency and thalassemia intermedia in a family.

Authors:  Yasser Abou Mourad; Ali Shamseddine; Ayad Hamdan; Susane Koussa; Ali Taher
Journal:  Ann Saudi Med       Date:  2004 Jul-Aug       Impact factor: 1.526

9.  Beta-Thalassemia Intermedia: A Single Thalassemia Center Experience from Northeastern Iraq.

Authors:  Shaema Salih Amin; Sana Dlawar Jalal; Kosar Muhammed Ali; Ali Ibrahim Mohammed; Luqman Khalid Rasool; Tara Jamel Osman
Journal:  Biomed Res Int       Date:  2020-02-28       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.